Latest Breaking News On - Yuankai shi - Page 2 : comparemela.com

Share this article Share this article SAN FRANCISCO and SUZHOU, China, Jan. 11, 2021 /PRNewswire/ Innovent Biologics, Inc. ( Innovent , HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announced with Eli Lilly and Company ( Lilly ,NYSE: LLY) that the National Medical Products Administration (NMPA) of China has accepted the supplemental New Drug Application (sNDA) for TYVYT® (sintilimab injection) as second-line therapy for squamous non-small cell lung cancer (sqNSCLC). The application is the third sNDA for TYVYT® (sintilimab injection) in NSCLC. This sNDA was based on a randomized, open-label, Phase 3 clinical trial (ORIENT-3) evaluating TYVYT® (sintilimab injection) as second-line therapy for patients with advanced or recurrent sqNSCLC whose cancer had progressed on first-line platinum-based chemotherapy. Based on the

United statesHong kongWang liAdimab incyteYuankai shiEli lillyCompany lillyPrnewswire innovent biologics incMd anderson cancer centerCatalogue of the national reimbursement drug listNational reimbursement drug listHead of lilly china drug developmentNational medical products administrationChinese academy of medical sciencesNew drug applicationProfessor yuankai shi